NIAGARA FALLS, N.Y., Sept. 27, 2018 /PRNewswire/ -- Positron Corporation (OTC :POSC )(the "Company"), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward. Adel Abdullah has been instrumental to Positron's ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron's customers.

Positron is also pleased to announce the appointment of Aaron Hargrave, Positron's Director of Clinical Applications as Vice President. Mr. Hargrave is a Certified Nuclear Medicine Technologist, performing PET imaging in cardiac, oncology and neurologic subsets for Positron since 2010. Mr. Hargrave provides clinical and software support and training for Positron's Attrius PET customers specializing in image quality and interpreting technical data, ensuring proper product use for optimal patient outcomes.

Mr. Abdullah and Mr. Hargrave have delivered top performing PET technology used in over 50,000 cardiac studies on Positron imaging systems.
Mr. Abdullah stated, "It is an exciting time at Positron. As a company we are on a new path that I expect will have great impact in the growth of the cardiac PET industry. Positron is stronger than ever with the ability to focus exclusively on its imaging technology, clinical services and innovative pro-business structures for its customers. Our goal is to work with champions of the cardiac PET industry to advance the adoption of cardiac PET utilizing Positron's PET imaging systems and services."


About Positron:
Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron. Positron is redefining the industry.


SOURCE Positron Corporation

Molecular Imaging Homepage